$3.72
+0.08
(+2.2%)▲
3.23%
Downside
Day's Volatility :3.74%
Upside
0.53%
40.32%
Downside
52 Weeks Volatility :78.11%
Upside
63.31%
Period | Curevac | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 56.22% | 6.5% | 0.0% |
6 Months | 1.96% | 7.1% | 0.0% |
1 Year | -57.23% | 9.8% | 0.0% |
3 Years | -93.28% | 14.2% | -20.2% |
Market Capitalization | 807.5M |
Book Value | $1.99 |
Earnings Per Share (EPS) | -1.33 |
Wall Street Target Price | 8.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -623.03% |
Return On Assets TTM | -21.53% |
Return On Equity TTM | -47.11% |
Revenue TTM | 59.0M |
Revenue Per Share TTM | 0.26 |
Quarterly Revenue Growth YOY | 73.6% |
Gross Profit TTM | -91.5M |
EBITDA | -270.8M |
Diluted Eps TTM | -1.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.01 |
EPS Estimate Next Year | -0.61 |
EPS Estimate Current Quarter | -0.25 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 123.92%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 14.7M | - |
Net Income | -81.5M | - |
Net Profit Margin | -553.5% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 19.5M | ↑ 35.31% |
Net Income | -111.9M | ↑ 40.19% |
Net Profit Margin | -573.46% | ↓ 19.96% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 60.1M | ↑ 180.78% |
Net Income | -158.8M | ↑ 29.24% |
Net Profit Margin | -263.96% | ↑ 309.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 116.6M | ↑ 110.61% |
Net Income | -466.3M | ↑ 218.98% |
Net Profit Margin | -399.76% | ↓ 135.8% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 72.2M | ↓ 34.54% |
Net Income | -266.8M | ↓ 39.51% |
Net Profit Margin | -369.37% | ↑ 30.39% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 52.7M | ↓ 21.9% |
Net Income | -254.8M | ↑ 2.33% |
Net Profit Margin | -483.96% | ↓ 114.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.5M | ↑ 4.25% |
Net Income | -138.0M | ↑ 170.74% |
Net Profit Margin | -1.1K% | ↓ 677.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.7M | ↑ 0.0% |
Net Income | -140.4M | ↑ 0.0% |
Net Profit Margin | -1.1K% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.3M | ↓ 35.16% |
Net Income | -73.6M | ↓ 47.65% |
Net Profit Margin | -889.48% | ↑ 212.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.5M | ↑ 117.48% |
Net Income | -48.7M | ↓ 27.79% |
Net Profit Margin | -295.34% | ↑ 594.14% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.6M | ↑ 36.91% |
Net Income | -86.7M | ↑ 78.0% |
Net Profit Margin | -383.98% | ↓ 88.64% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 23.7M | ↓ 2.57% |
Net Income | -91.2M | ↓ 2.57% |
Net Profit Margin | -383.98% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 143.8M | - |
Total Liabilities | 107.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 146.3M | ↑ 3.95% |
Total Liabilities | 194.3M | ↑ 85.33% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 1057.06% |
Total Liabilities | 984.0M | ↑ 361.31% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 23.36% |
Total Liabilities | 532.0M | ↓ 41.28% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 921.8M | ↓ 25.71% |
Total Liabilities | 350.5M | ↓ 30.34% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 788.9M | ↓ 8.32% |
Total Liabilities | 271.5M | ↓ 17.02% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 921.8M | ↓ 5.5% |
Total Liabilities | 350.5M | ↑ 14.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 938.4M | ↑ 0.0% |
Total Liabilities | 356.8M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 981.4M | ↑ 4.53% |
Total Liabilities | 273.2M | ↓ 23.47% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 842.6M | ↓ 6.33% |
Total Liabilities | 240.3M | ↓ 4.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 788.2M | ↓ 6.45% |
Total Liabilities | 271.3M | ↑ 12.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 851.8M | ↑ 0.08% |
Total Liabilities | 293.2M | ↑ 0.08% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -84.8M | - |
Investing Cash Flow | -4.9M | - |
Financing Cash Flow | -128.1K | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -97.4M | ↑ 17.34% |
Investing Cash Flow | 31.6M | ↓ 760.91% |
Financing Cash Flow | 76.1M | ↓ 60795.54% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 642.6M | ↓ 700.72% |
Investing Cash Flow | -55.7M | ↓ 260.65% |
Financing Cash Flow | 1.0B | ↑ 1106.01% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -830.3M | ↓ 240.34% |
Investing Cash Flow | -144.8M | ↑ 182.5% |
Financing Cash Flow | 390.7M | ↓ 57.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -52.6M | ↑ 36.67% |
Investing Cash Flow | -14.4M | ↓ 51.8% |
Financing Cash Flow | 35.7M | ↑ 25.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -53.5M | ↑ 0.0% |
Investing Cash Flow | -14.6M | ↑ 0.0% |
Financing Cash Flow | 36.3M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -70.0M | ↑ 30.62% |
Investing Cash Flow | -14.6M | ↑ 0.0% |
Financing Cash Flow | -1.3M | ↓ 103.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -60.6M | ↓ 5.52% |
Investing Cash Flow | -13.4M | ↑ 0.0% |
Financing Cash Flow | -1.2M | ↑ 1.25% |
Sell
Neutral
Buy
Curevac is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Curevac | 8.17% | 1.96% | -57.23% | -93.28% | -93.49% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Curevac | NA | NA | NA | -0.01 | -0.47 | -0.22 | NA | 1.99 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Curevac | Buy | $807.5M | -93.49% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Curevac
Revenue is down for the last 2 quarters, 22.56M → 21.98M (in $), with an average decrease of 2.6% per quarter
Netprofit is up for the last 2 quarters, -86.65M → -84.42M (in $), with an average increase of 2.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 118.8%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 279.8%
Millennium Management LLC
BlackRock Inc
RA Capital Management, LLC
Camber Capital Management LLC
Bill & Melinda Gates Foundation
Morgan Stanley - Brokerage Accounts
founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o
Organization | Curevac |
Employees | 999 |
CEO | Mr. Pierre Kemula B.Sc. |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.72
+2.2%
Keyarch Acquisition Corp
$3.72
+2.2%
Connexa Sports Technologies Inc
$3.72
+2.2%
Us Value Etf
$3.72
+2.2%
First Wave Biopharma Inc
$3.72
+2.2%
Global X Msci Next Emerging
$3.72
+2.2%
Fat Projects Acquisition Corp
$3.72
+2.2%
Capital Link Global Fintech
$3.72
+2.2%
Applied Uv Inc
$3.72
+2.2%